Evolent Health (EVH) Stock Price Target 2026

The average analyst price target for Evolent Health is $10.78, 124.6% above the current price. Of 16 analysts, 14 rate it Buy and 2 Hold. Targets range from $3 to $28. The latest change came on Nov 6, 2026, when Oppenheimer raised its price target on Evolent Health from $6 to $7 and kept an Outperform rating.

The Average Analyst Price Target for Evolent Health is $10.78.

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

3S.Buy

11Buy

2Hold

Consensus RatingBuy# Analysts16Avg. Consensus PT$10.78Upside to Avg. PT+124.6%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Evolent Health Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 6, 2026	Oppenheimer	Michael Wiederhorn	PT Raise	Outperform	$6→$7
Nov 5, 2026	Needham	Matthew Shea	PT Raise	Buy	$5→$6
Aug 18, 2026	JP Morgan	John Stansel	PT Raise	Overweight	$5→$6
Aug 17, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$5→$6
Aug 12, 2026	Truist Securities	Jailendra Singh	PT Cut	Hold	$7→$6
Aug 11, 2026	Citigroup	Daniel Grosslight	Upgrade	Neutral→Buy	$7→$6
Aug 10, 2026	Canaccord Genuity	Richard Close	PT Cut	Buy	$7→$6
Jul 28, 2026	TD Cowen	Charles Rhyee	PT Cut	Buy	$8→$5
Jul 23, 2026	Citigroup	Daniel Grosslight	Downgrade	Buy→Neutral	$6→$7
Jul 21, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$6→$7
Jun 30, 2026	Truist Securities	Jailendra Singh	Downgrade	Buy→Hold	$7
Jun 12, 2026	Truist Securities	Jailendra Singh	PT Raise	Buy	$6→$7
May 15, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$6
May 12, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$4→$6
May 7, 2026	Needham	Matthew Shea	PT Raise	Buy	$4→$5
Mar 2, 2026	Oppenheimer	Michael Wiederhorn	PT Cut	Outperform	$12→$6
Feb 26, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$6→$4
Feb 26, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$10→$5
Feb 26, 2026	Truist Securities	Jailendra Singh	PT Cut	Buy	$10→$6
Feb 25, 2026	Needham	Matthew Shea	PT Cut	Buy	$15→$4